Immunology. Getting sepsis therapy right. Hotchkiss RS, Sherwood ER (2015) Science 347: 1201-2 Association of major depressive disorder with serum myeloperoxidase and other markers of inflammation: a twin study. Vaccarino V, Brennan ML, Miller AH, Bremner JD, Ritchie JC, Lindau F, Veledar E, Su S, Murrah NV, Jones L, Jawed F, Dai J, Goldberg J, Hazen SL (2008) Biol Psychiatry 64: 476-83 A phase I/II study of sequential interleukin-3 and granulocyte-macrophage colony-stimulating factor in myelodysplastic syndromes. Nand S, Sosman J, Godwin JE, Fisher RI (1994) Blood 83: 357-60 Protein phosphatase 2A activates the proapoptotic function of BAD in interleukin- 3-dependent lymphoid cells by a mechanism requiring 14-3-3 dissociation. Chiang CW, Harris G, Ellig C, Masters SC, Subramanian R, Shenolikar S, Wadzinski BE, Yang E (2001) Blood 97: 1289-97 Partially differentiated ex vivo expanded cells accelerate hematologic recovery in myeloablated mice transplanted with highly enriched long-term repopulating stem cells. Szilvassy SJ, Weller KP, Chen B, Juttner CA, Tsukamoto A, Hoffman R (1996) Blood 88: 3642-53 The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Cortez D, Reuther G, Pendergast AM (1997) Oncogene 15: 2333-42 Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1. Eischen CM, Packham G, Nip J, Fee BE, Hiebert SW, Zambetti GP, Cleveland JL (2001) Oncogene 20: 6983-93 E2F-1:DP-1 induces p53 and overrides survival factors to trigger apoptosis. Hiebert SW, Packham G, Strom DK, Haffner R, Oren M, Zambetti G, Cleveland JL (1995) Mol Cell Biol 15: 6864-74 Interaction between interleukin 3 and dystrobrevin-binding protein 1 in schizophrenia. Edwards TL, Wang X, Chen Q, Wormly B, Riley B, O'Neill FA, Walsh D, Ritchie MD, Kendler KS, Chen X (2008) Schizophr Res 106: 208-17 A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy. Sosman JA, Stiff PJ, Bayer RA, Peliska J, Peace DJ, Loutfi S, Stock W, Oldenburg D, Unverzagt K, Bender J (1995) Bone Marrow Transplant 16: 655-61 Topoisomerase IIalpha mediates E2F-1-induced chemosensitivity and is a target for p53-mediated transcriptional repression. Nip J, Hiebert SW (2000) Cell Biochem Biophys 33: 199-207
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.